Literature DB >> 32443023

Risk Stratification and Personal Protective Equipment Use in Pediatric Endoscopy During the Coronavirus Disease 2019 Outbreak: A Single-center Protocol.

Daphne S Say1,2,3, Arthur de Lorimier1,2,3, Cathleen R Lammers2,4,3, JoAnne Natale5,2,3, Satyan Lakshminrusimha6,2,3, Jean Wiedeman7,2,3, Elizabeth Partridge7,2,3.   

Abstract

SARS-CoV-2, the novel coronavirus causing coronavirus disease 2019 (COVID-19), is now a global pandemic. Human-to-human transmission has been documented to occur through respiratory secretions, feces, aerosols, and contaminated environmental surfaces. Pediatric patients present a unique challenge as they may have minimal symptoms and yet transmit disease. Endoscopists face risk for infection with viruses like SARS-CoV-2, as the aerosol generating nature of endoscopy diffuses respiratory disease that can be spread via an airborne and droplet route. We describe our center's methodology for pediatric patient risk stratification to facilitate responsible use of endoscopic resources during this crisis. We also describe our recommendations for use of personal protective equipment by endoscopists, with the goal of ensuring the safety of ourselves, our anesthesiology and endoscopy staff, and our patients.

Entities:  

Mesh:

Year:  2020        PMID: 32443023      PMCID: PMC7273944          DOI: 10.1097/MPG.0000000000002731

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   3.288


SARS-CoV-2, the novel coronavirus causing coronavirus disease 2019 (COVID-19), is now a global pandemic. Human-to-human transmission has been documented to occur through respiratory secretions, feces, aerosols, and contaminated environmental surfaces (1,2). Transmission can occur from both symptomatic and asymptomatic individuals (3). The risk of infection to healthcare providers (HCP) is substantial: in one of the earliest documentations of infection in Wuhan, China, 29% of patients were healthcare workers (4). It is unclear how much of the risk was related to community transmission or to breaches in use of personal protective equipment (PPE) during the care of patients with COVID-19. It appears inevitable that, when performing endoscopy, HCP will be exposed to either respiratory or gastrointestinal fluids from patients. Thus, adequate protection of HCP during endoscopic procedures is now critical. An Italian group has provided recommendations regarding the safe performance of endoscopy of adult patients during the COVID-19 outbreak (5). Pediatric patients requiring endoscopy represent a unique challenge, as they are disproportionately asymptomatic or mildly ill if infected, yet can still transmit disease (6). Despite the need for mobilization of resources to address this pandemic, there remain children who require ongoing care and evaluation from a specialized gastroenterology team, including endoscopy. Delaying such procedures may compromise patient health and strain future resources. The inability to predict when the surge in community infection and demand for hospital resources will occur further complicates care decisions. We here report our methods for pediatric patient risk stratification and associated utilization of PPE to facilitate responsible and safe procedures for patients in this pandemic. It is based on review of the available and relevant literature, primarily from China, and local experience.

RISK STRATIFICATION AND PERSONAL PROTECTIVE EQUIPMENT DURING ENDOSCOPY

There are currently no reports in the literature of SARS-CoV-2 infection directly linked to an endoscopic exposure. As endoscopy is an aerosol-generating procedure (AGP), the risk for infection, however, remains. Coughing and retching during upper endoscopy generates aerosols (7). Patients undergoing colonoscopy may pass flatus or liquid stool, which disseminates organisms to nearby surroundings. Fecal carriage of SARS-CoV-2 has been documented, implying that the virus actively replicates in the gastrointestinal tract even after viral clearance in the respiratory tract (8). Recently, the World Health Organization (WHO) has published guidelines for rational use of PPE for COVID-19, including specific instructions for healthcare workers performing AGP on patients with known/documented COVID-19 (9). These include the use of a respirator (N95 respirator or equivalent), water-resistant gown, gloves, and eye protection for personnel in the endoscopy suite. At the same time, we also recognize the need to conserve PPE and other needed resources in anticipation of the surge of COVID-19 patients that require hospitalization. This report is designed to ensure the safety of ourselves, our anesthesiology and endoscopy staff, and our patients without overly taxing front-line responders’ need for PPE during this crisis. In the absence of routine viral testing, in keeping with guidelines outlined by Repici et al (5), we stratify the patient's COVID-19 risk based on symptoms and sick contacts (Table 1). Decisions regarding appropriate PPE use are then made based on the patient's assessed risk (Fig. 1). Our proposed stratification takes into account the higher probability that an asymptomatic or mildly ill child may be infected with SARS-CoV-2 and is infectious. Review of the data from Wuhan, China reveals that nearly 18% of all children with SARS-CoV-2 infection are asymptomatic (3). Given initial limitations in the availability of testing for SARS-CoV-2 infection, however, our institution's current screening algorithm specifies testing only individuals with influenza-like illness and exposure to a patient with known COVID-19. As our own lab-developed testing capabilities increase, we anticipate future modifications of our pre-procedure screening to incorporate oropharyngeal and nasopharyngeal swabs for SARS-CoV-2 infection. Stool testing, along with anal swab tests, may also present future preprocedure screening possibilities.
TABLE 1

SARS-CoV-2 infection risk in pediatric patients requiring endoscopy

FIGURE 1

Personal protective equipment utilization algorithm for endoscopists.

SARS-CoV-2 infection risk in pediatric patients requiring endoscopy Personal protective equipment utilization algorithm for endoscopists. We advise placing a surgical mask on the high-risk and unknown risk patient for transport in and out of the procedure room. We limit all nonessential personnel for all procedures, with no more than 5 individuals in the endoscopy suite at a time. We recommend use of a negative pressure room, rather than a positive pressure room, for all endoscopic procedures (Fig. 2). A neutral pressure room with the door closed may be used if all personnel in the room don a powered air-purifying respirator (PAPR) in lieu of hair covering, N95 respirator, and eye protection, as well as using a water-resistant gown and double layer of gloves. This room would need to remain closed for 1 h after the procedure is complete to allow enough air exchange to evacuate suspended infectious particles. Appropriate signage should be placed outside the procedure room, indicating to others that an AGP is occurring (Fig. 3).
FIGURE 2

Personal protective equipment utilization in the endoscopy suite.

FIGURE 3

Aerosol generating procedure notification.

Personal protective equipment utilization in the endoscopy suite. Aerosol generating procedure notification.

SCHEDULING OF ENDOSCOPIC PROCEDURES

In an effort to support patient-centered care, we plan to perform all previously scheduled and new outpatient endoscopic procedures that are deemed “essential” for as long as adequate PPE resources described in these recommendations will allow. We define “essential” endoscopic procedures as those that, if delayed more than 8 to 12 weeks, would predispose a child to harm or injury. Should the status of available PPE or provider workforce change, we anticipate limiting our procedures only to “emergent” procedures (eg, foreign body removal, gastrointestinal bleeding, diagnostic procedures in hospitalized patients). We will also review the risks and benefits of endoscopy with our patients’ families in advance of procedure, as well as the potential risks of exposure to SARS-CoV-2 associated with nonadherence to the public health recommendations to “shelter in place.” Many patients’ families may choose to reschedule procedures until after current social distancing restrictions have been lifted. If a patient's endoscopic procedure is delayed, we will regularly assess the patient's clinical status to ensure safety and provide necessary supportive measures in the interim. We have created a registry to enable monitoring of affected patients via telemedicine evaluation and to facilitate future procedure rescheduling.

SUMMARY OF RECOMMENDATIONS

If viral testing for SARS-CoV-2 infection is not available, patient risk stratification before endoscopy may be accomplished based on symptoms and sick contacts. Emergent procedures, including but not limited to foreign body retrieval, diagnostic and therapeutic evaluation of gastrointestinal bleeding, and procedures in hospitalized patients should be prioritized. We suggest limiting outpatient procedures only to “essential” procedures (defined as procedures that, if delayed more than 8--12 weeks, would lead to harm or injury). Ultimately, final decisions regarding the scheduling and timing of endoscopy will be made through shared decision-making between the individual gastroenterologist, patient, and the patient's family. At minimum, those in the pediatric endoscopy suite will require use of gloves, water-resistant gowns, surgical face masks, eye protection, and hair coverings for all endoscopic procedures. For low-risk and high-risk patients requiring upper endoscopy and high-risk patients requiring colonoscopy, endoscopists will utilize N95 respirators (in lieu of surgical face masks) or equivalent in addition to the PPE listed above. PAPR may take the place of surgical face masks/N95 respirators, eye protection, and hair coverings.
  6 in total

1.  Risk of bacterial exposure to the endoscopist's face during endoscopy.

Authors:  Elyse R Johnston; Nadia Habib-Bein; Jeffrey M Dueker; Barbara Quiroz; Enrico Corsaro; Megan Ambrogio; Michael Kingsley; Georgios I Papachristou; Christianna Kreiss; Asif Khalid
Journal:  Gastrointest Endosc       Date:  2018-11-01       Impact factor: 9.427

2.  COVID-19-New Insights on a Rapidly Changing Epidemic.

Authors:  Carlos Del Rio; Preeti N Malani
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

3.  Presumed Asymptomatic Carrier Transmission of COVID-19.

Authors:  Yan Bai; Lingsheng Yao; Tao Wei; Fei Tian; Dong-Yan Jin; Lijuan Chen; Meiyun Wang
Journal:  JAMA       Date:  2020-04-14       Impact factor: 56.272

4.  A 55-Day-Old Female Infant Infected With 2019 Novel Coronavirus Disease: Presenting With Pneumonia, Liver Injury, and Heart Damage.

Authors:  Yuxia Cui; Maolu Tian; Dong Huang; Xike Wang; Yuying Huang; Li Fan; Liang Wang; Yun Chen; Wenpu Liu; Kai Zhang; Yue Wu; Zhenzhong Yang; Jing Tao; Jie Feng; Kaiyu Liu; Xianwei Ye; Rongpin Wang; Xiangyan Zhang; Yan Zha
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

5.  Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2).

Authors:  Ruiyun Li; Sen Pei; Bin Chen; Yimeng Song; Tao Zhang; Wan Yang; Jeffrey Shaman
Journal:  Science       Date:  2020-03-16       Impact factor: 47.728

6.  Prolonged presence of SARS-CoV-2 viral RNA in faecal samples.

Authors:  Yongjian Wu; Cheng Guo; Lantian Tang; Zhongsi Hong; Jianhui Zhou; Xin Dong; Huan Yin; Qiang Xiao; Yanping Tang; Xiujuan Qu; Liangjian Kuang; Xiaomin Fang; Nischay Mishra; Jiahai Lu; Hong Shan; Guanmin Jiang; Xi Huang
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-03-20
  6 in total
  2 in total

Review 1.  Pediatric Endoscopy During COVID-19 Times.

Authors:  Ron Shaoul; Andrew S Day
Journal:  Front Pediatr       Date:  2021-12-16       Impact factor: 3.418

Review 2.  Coronavirus disease 2019 (COVID-19) and pediatric gastroenterology.

Authors:  Pejman Rohani; Sara Ahmadi Badi; Arfa Moshiri; Seyed Davar Siadat
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.